Clinical Trials Browser

Phase 3 × MDS × Azacitidine × Clear all

NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Phase 3 Completed

154 enrolled 10 charts

MDS